HRS-8080 + SHR-A1811

HRS-8080 + SHR-A1811 is a combination therapy of two investigational anticancer agents under clinical evaluation, primarily for advanced unresectable or metastatic breast cancer. **HRS-8080** is a novel, potent, selective oral small molecule degrader of estrogen receptors (ER), designed to inhibit ER signaling and proliferation of ER-positive and ER-mutant breast cancer cells[2][4]. **SHR-A1811** is an antibody-drug conjugate (ADC) composed of a trastuzumab-based anti-HER2 monoclonal antibody, a cleavable linker, and a topoisomerase I inhibitor payload; it targets and kills HER2-expressing cancer cells through HER2-directed delivery of the cytotoxic agent[3][5]. The combination aims to address tumors with hormone receptor positivity and/or HER2 overexpression or mutation, and is currently being studied for safety, tolerability, and efficacy in this patient population[1][7].

Other names

HRS 8080 + SHR A1811HRS8080 + SHRA1811